A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan

International Journal of Stroke

Volumn 7, Issue 2, 2012, Pages 104-111

  Beer, Christopher ^a,b,c,d   Blacker, David ^b,e   Bynevelt, Michael ^d,e   Hankey, Graeme J ^b,d   Puddey, Ian B ^b,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Acute Cerebral Infarction; Antihypertensive; Atorvastatin; Irbesartan; Lipid lowering therapy; Therapy

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; IRBESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMISPHERE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PYRROLES; SAMPLE SIZE; STROKE; TETRAZOLES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84856147735     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00653.x     Document Type: Article

References (39)

1. Mathers CD, Vos ET, Stevenson CE, Begg SJ.The burden of disease and injury in Australia. Bull World Health Organ 2001; 79:1076-84.
2. Amarenco P, Bogousslavsky J, Callahan AIIIet al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-59.
3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-41.
4. Vaughan CJ, Delanty N.Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30:1969-73.
5. Faggiotto A, Paoletti R.State-of-the-art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999; 34:987-96.
6. Chen J, Zhang ZG, Li Yet al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53:743-51.
7. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 2005; 19:923-31.
8. Pretnar-Oblak J, Sabovic M, Sebestjen M, Pogacnik T, Zaletel M.Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 2006; 37:2540-5.
9. Murakami M, Fujioka S, Hirata Y, Kuratsu J.Low-dose of statin treatment improves cerebrovascular reactivity in patients with ischemic stroke: single photon emission computed tomography analysis. J Stroke Cerebrovasc Dis 2008; 17:16-22.
10. Berger C, Xia F, Maurer MH, Schwab S.Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res Rev 2008; 58:48-56.
11. Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y.Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res 2007; 1169:125-32.
12. Derdeyn CP, Carpenter DA, Videen TO, Grubb RLJr., Powers WJ.No effect of low-dose statins treatment on cerebral blood flow in humans with atherosclerotic cerebrovascular disease. J Cereb Blood Flow Metab 2007; 27:1643-8.
13. ten Dam VH, Box FM, de Craen AJet al. Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease. Stroke 2005; 36:1633-6.
14. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM.Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961-9.
15. Montaner J, Chacon P, Krupinski Jet al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008; 15:82-90.
16. Schrader J, Luders S, Kulschewski Aet al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in stroke survivors. Stroke 2003; 34:1699-703.
17. Dyker AG, Grosset DG, Lees K.Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997; 28:580-3.
18. Eveson DJ, Robinson TG, Potter JF.Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens 2007; 20:270-7.
19. Nazir FS, Overell JR, Bolster A, Hilditch TE, Reid JL, Lees KR.The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. J Hypertens 2004; 22:989-95.
20. Nazir FS, Overell JR, Bolster A, Hilditch TE, Lees KR.Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial. Cerebrovasc Dis 2005; 19:77-83.
21. Saver JL, Johnston KC, Homer Det al. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke 1999; 30:293-8.
22. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C.Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337:1521-6.
23. Adams HP Jr., Bendixen BH, Kappelle LJet al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35-41.
24. Brott T, Adams HPJr., Olinger CPet al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864-70.
25. Cherian P, Hankey GJ, Eikelboom JWet al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003; 34:2132-7.
26. Goodwin J, Bilous M, Winship S, Finn P, Jones SC.Validation of the Oscar 2 oscillometric 24-h ambulatory blood pressure monitor according to the British Hypertension Society protocol. Blood Press Monit 2007; 12:113-7.
27. Jones SC, Bilous M, Winship S, Finn P, Goodwin J.Validation of the OSCAR 2 oscillometric 24-hour ambulatory blood pressure monitor according to the International Protocol for the validation of blood pressure measuring devices. Blood Press Monit 2004; 9:219-23.
28. Hillis AE, Wityk RJ, Beauchamp NJ, Ulatowski JA, Jacobs MA, Barker PB.Perfusion-weighted MRI as a marker of response to treatment in acute and subacute stroke. Neuroradiology 2004; 46:31-9.
29. Warach S. Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials. Curr Control Trials Cardiovasc Med 2001; 2:38-44.
30. Chyrchel M, Dudek D, Bartus S, Legutko J, Heba G, Dubiel JS.High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina. Kardiol Pol 2004; 61:213-21.
31. Ordulu E, Erdogan O.Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. Int J Cardiol 2008; 128:282-4.
32. Laufs U, Liao JK.Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol 2003; 23:156-7.
33. Sironi L, Cimino M, Guerrini Uet al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003; 23:322-7.
34. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH.Reduction in blood pressure with statins: results from the UCSD statin study, a randomized trial. Arch Intern Med 2008; 168:721-7.
35. Wintermark M, Flanders AE, Velthuis Bet al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006; 37:979-85.
36. Matsumoto S, Shimodozono M, Miyata R, Kawahira K.Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. Hypertens Res 2009; 32:1015-21.
37. Walters MR, Bolster A, Dyker AG, Lees KR.Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke 2001; 32:473-8.
38. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M.Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005; 62:1130-4.
39. Jovin TG, Yonas H, Gebel JMet al. The cortical ischemic core and not the consistently present penumbra is a determinant of clinical outcome in acute middle cerebral artery occlusion. Stroke 2003; 34:2426-33.